Clinical trial
Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation
NCT00656175 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation
- Lead sponsor
- University of California, Los Angeles
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2008
- Completion date
- December 31, 2011
- Enrollment
- 39 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.